1
|
Anemüller R, Belden K, Brause B, Citak M, Del Pozo JL, Frommelt L, Gehrke T, Hewlett A, Higuera CA, Hughes H, Kheir M, Kim KI, Konan S, Lausmann C, Marculescu C, Morata L, Ramirez I, Rossmann M, Silibovsky R, Soriano A, Suh GA, Vogely C, Volpin A, Yombi J, Zahar A, Zimmerli W. Hip and Knee Section, Treatment, Antimicrobials: Proceedings of International Consensus on Orthopedic Infections. J Arthroplasty 2019; 34:S463-S475. [PMID: 30348582 DOI: 10.1016/j.arth.2018.09.032] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
|
2
|
Esposito S, Russo E, De Simone G, Gioia R, Petta E, Leone S, Noviello S, Artioli S, Ascione T, Bartoloni A, Bassetti M, Bertelli D, Boccia G, Borrè S, Brugnaro P, Caramello P, Coen M, Crisalli MP, De Caro F, Dodi F, Fantoni M, Foti G, Giacometti A, Leoncini F, Libanore M, Migliore S, Venditti M. Diagnostic and therapeutic appropriateness in bone and joint infections: results of a national survey. J Chemother 2017; 28:191-7. [PMID: 25800800 DOI: 10.1179/1973947815y.0000000012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
The impact of infectious diseases (ID) specialist consultation in the management of many types of bacterial infections has been fully demonstrated but not for bone and joint infections (BJIs). Nineteen ID Italian centres collected of data from June 2009 to May 2012. Italian guidelines (2009) were used to determine the appropriateness of the diagnostic and therapeutic process of BJIs before and after consulting an ID specialist. Data on 311 patients were collected: 111 cases of prosthetic joint infection, 99 osteomyelitis, 64 spondylodiscitis and 37 fixation device infection. A significant increase of microbiological investigations, imaging techniques and blood inflammation markers were noted after consulting the ID specialist. Moreover, inappropriateness of treatment duration, dosage, and number of administrations significantly decreased after consultation. Infectious disease specialist intervention in the management of BJIs significantly increases the appropriateness both in performing instrumental and laboratory analysis, but especially in determining the correct therapy.
Collapse
Affiliation(s)
- Silvano Esposito
- a Infectious Diseases Unit , University of Salerno, San Giovanni di Dio e Ruggi d'Aragona Hospital, Salerno , Italy
| | - Enrico Russo
- a Infectious Diseases Unit , University of Salerno, San Giovanni di Dio e Ruggi d'Aragona Hospital, Salerno , Italy
| | - Giuseppe De Simone
- a Infectious Diseases Unit , University of Salerno, San Giovanni di Dio e Ruggi d'Aragona Hospital, Salerno , Italy
| | - Renato Gioia
- a Infectious Diseases Unit , University of Salerno, San Giovanni di Dio e Ruggi d'Aragona Hospital, Salerno , Italy
| | - Ester Petta
- a Infectious Diseases Unit , University of Salerno, San Giovanni di Dio e Ruggi d'Aragona Hospital, Salerno , Italy
| | - Sebastiano Leone
- a Infectious Diseases Unit , University of Salerno, San Giovanni di Dio e Ruggi d'Aragona Hospital, Salerno , Italy
| | - Silvana Noviello
- a Infectious Diseases Unit , University of Salerno, San Giovanni di Dio e Ruggi d'Aragona Hospital, Salerno , Italy
| | - Stefania Artioli
- b Infectious Diseases Unit , Levante Ligure Hospital, Levante Ligure , Italy
| | - Tiziana Ascione
- c Infectious Diseases Unit , Cotugno Hospital, Naples , Italy
| | - Alessandro Bartoloni
- d Infectious Diseases Unit , University of Florence, Careggi Hospital, Florence , Italy
| | - Matteo Bassetti
- e Infectious Diseases Unit , AOU Santa Maria della Misericordia, Udine , Italy
| | - Davide Bertelli
- f Infectious Diseases Unit , A. O. Spedali Civili, Brescia , Italy
| | - Giovanni Boccia
- g Hygiene Unit , University of Salerno, San Giovanni di Dio e Ruggi d'Aragona Hospital, Salerno , Italy
| | - Silvio Borrè
- h Infectious Diseases Unit , S. Andrea Hospital, Vercelli , Italy
| | - Pierluigi Brugnaro
- i Infectious Diseases Unit , "SS. Giovanni e Paolo" Hospital, Castello, Venice , Italy
| | - Pietro Caramello
- j Infectious Diseases Unit , Amedeo di Savoia Hospital, Turin , Italy
| | - Massimo Coen
- k Infectious Diseases Unit , Sacco Hospital, Milan , Italy
| | | | - Francesco De Caro
- g Hygiene Unit , University of Salerno, San Giovanni di Dio e Ruggi d'Aragona Hospital, Salerno , Italy
| | - Ferdinando Dodi
- m Infectious Diseases Unit , IRCCS San Martino, Genoa , Italy
| | - Massimo Fantoni
- n Infectious Diseases Institute, Catholic S. Cuore, Gemelli Hospital , Rome , Italy
| | - Giuseppe Foti
- o Infectious Diseases Unit , Bianchi Melacrino Morelli Hospital, Reggio Calabria , Italy
| | | | | | - Marco Libanore
- r Infectious Diseases Unit , University of Ferrara, Ferrara , Italy
| | - Simona Migliore
- s Infectious Diseases Unit , Ragusa Hospital, Ragusa , Italy
| | - Mario Venditti
- t Infectious Diseases Institute, University of Rome La Sapienza , Rome , Italy
| |
Collapse
|
3
|
Kheir MM, Tan TL, Higuera C, George J, Della Valle CJ, Shen M, Parvizi J. Periprosthetic Joint Infections Caused by Enterococci Have Poor Outcomes. J Arthroplasty 2017; 32:933-947. [PMID: 27789094 DOI: 10.1016/j.arth.2016.09.017] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/14/2016] [Revised: 09/07/2016] [Accepted: 09/12/2016] [Indexed: 02/01/2023] Open
Abstract
BACKGROUND The definitive treatment and outcome of periprosthetic joint infection (PJI) caused by Enterococcus species is unknown. We performed a multi-institutional study to analyze the characteristics and treatment outcomes of patients with enterococcal PJI and to define an effective treatment protocol. METHODS We retrospectively reviewed all PJIs at 3 institutions between 1999 and 2014 using an electronic query followed by manual chart review. We included patients who met the Musculoskeletal Infection Society's criteria for PJI and had at least 1 positive intraoperative culture for any Enterococcus species. We identified 87 patients who had 12-month follow-up or treatment failure (mean, 4.03 years). Treatment failure was based on Delphi consensus criteria described previously. Kaplan-Meier survivorship analyses were performed. We assumed an alpha level of 0.05 for statistical significance. RESULTS The overall incidence of enterococcal PJI was 4.2%. The overall treatment success rate was 51.7% (45 of 87 patients). Thirteen cases (14.9%) that failed treatment had adverse outcomes including salvage procedures and PJI-related mortality. Treatment success rates stratified by procedure were 62.8%, 39.4%, and 45.5% for 2-stage exchange arthroplasty, irrigation and debridement, and 1-stage exchange arthroplasty, respectively (P = .037). Antibiotic treatment was heterogeneous; although combination antibiotics demonstrated a trend toward higher treatment success, it was not statistically different from monotherapy regimens (P = .174). CONCLUSION Enterococcal PJI has a high rate of treatment failure. Surgeons and patients should be aware of the difficulty in managing this condition and its dismal treatment outcomes. Although antibiotic treatment was heterogeneous, there was a trend toward higher success rates when combination antibiotic therapy was used.
Collapse
Affiliation(s)
- Michael M Kheir
- The Rothman Institute at Thomas Jefferson University, Philadelphia, Pennsylvania
| | - Timothy L Tan
- The Rothman Institute at Thomas Jefferson University, Philadelphia, Pennsylvania
| | - Carlos Higuera
- Department of Orthopaedic Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio
| | - Jaiben George
- Department of Orthopaedic Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio
| | | | - Mary Shen
- Midwest Orthopaedics at Rush University, Chicago, Illinois
| | - Javad Parvizi
- The Rothman Institute at Thomas Jefferson University, Philadelphia, Pennsylvania
| |
Collapse
|
4
|
Sader H, Moet G, Jones R. Antimicrobial Resistance among Gram-Positive Bacteria Isolated in Latin American Hospitals. J Chemother 2013; 21:611-20. [DOI: 10.1179/joc.2009.21.6.611] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
5
|
Cilli F, Aydemir S, Tunger A. In VitroActivity of Daptomycin Alone and in Combination with Various Antimicrobials Against Gram-Positive Cocci. J Chemother 2013. [DOI: 10.1179/joc.2008.18.1.27] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
6
|
Yezli S, Shibl AM, Livermore DM, Memish ZA. Antimicrobial resistance among Gram-positive pathogens in Saudi Arabia. J Chemother 2012; 24:125-36. [PMID: 22759756 DOI: 10.1179/1973947812y.0000000010] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Several species of Gram-positive cocci are major nosocomial or community pathogens associated with morbidity and mortality. Here, we review the antimicrobial resistance among these pathogens in Saudi Arabia. In the last decades, antimicrobial resistance has increased among Staphylococcus aureus in the Kingdom with a growing prevalence of both nosocomial and community methicillin-resistant S. aureus (MRSA) isolates. As yet, no vancomycin-resistant MRSA have been reported, although isolates with reduced susceptibility to the drug have been noted. Currently, the prevalence of vancomycin-resistant entrococci (VRE) is low; however, VRE has been described in the Kingdom as well as Enterococcus faecalis and E. faecium isolates with high-level resistance to penicillin, sulfamethoxazole, macrolides, tetracycline, and aminoglycosides. In recent decades, the prevalence and rate of penicillin resistance and non-susceptibility among Streptococcus pneumoniae isolates have increased in Saudi Arabia. The organism remains, however, susceptible to other beta-lactams and to quinolones. On the other hand, resistance to co-trimoxazole and tetracyclines is high and resistance to macrolides is on the increase.
Collapse
|
7
|
Abstract
Multi-antibiotic resistant Gram-positive cocci, which include Staphylococcus aureus, the coagulase-negative staphylococcal group, Enterococcus faecalis and Enterococcus faecium, and other streptococci, represent emerging pathogens especially in the setting of the immunocompromised, hospitalized patients, in particular when surgery, invasive procedures, or prosthetic implants are of concern, patients are admitted in intensive care units, or underlying chronic disorders and immunodeficiency are of concern, and broad-spectrum antibiotics or immunosuppressive drugs are widely administered. During the recent years, the phenomenon of multiresistant Gram-positive cocci is spreading to the community, where the retrieval of such microorganism is progressively increasing. The spectrum of available antimicrobial compounds for an effective management of these relevant infections is significantly impaired in selection and clinical efficacy by the emerging and spread of methicillin-resistant and more recently glycopeptide-resistant Gram-positive microbial strains. The first oxazolidinone derivative linezolid, together with the recently licensed quinupristin–dalfopristin, daptomycin, and tigecycline, followed by a number of glycopeptides, fluoroquinolones, and other experimental compounds on the pipeline, represent an effective response to the great majority of these concerns, due to their innovative mechanisms of action, their maintained or enhanced activity against multiresistant pathogens, their effective pharmacokinetic/pharmacodynamic properties, their frequent possibility of synergistic activity with other compounds effective against Gram-positive pathogens, and a diffuse potential for a safe and easy administration, also when compromised patients are of concern. The main problems related to the epidemiological and clinical features of multiresistant Gram-positive infection, the potential clinical indications of all recently available compounds compared with the standard of care of treatment of resistant Gram-positive infections, and updated data on efficacy and tolerability of linezolid as the golden standard compound for vancomycin-resistant Gram-positive cocci in multiple clinical situations, are outlined and updated on the ground of an extensive review of all the available, recent evidences coming from the international literature.
Collapse
Affiliation(s)
- Roberto Manfredi
- Department of Clinical and Experimental Medicine, Division of Infectious Diseases, "Alma Mater Studiorum" University of Bologna, S. Orsola-Malpighi Hospital Bologna, Italy
| |
Collapse
|
8
|
Ippolito G, Leone S, Lauria FN, Nicastri E, Wenzel RP. Methicillin-resistant Staphylococcus aureus: the superbug. Int J Infect Dis 2010; 14 Suppl 4:S7-11. [PMID: 20851011 DOI: 10.1016/j.ijid.2010.05.003] [Citation(s) in RCA: 125] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Over the last decade, methicillin-resistant Staphylococcus aureus (MRSA) strains have emerged as serious pathogens in the nosocomial and community setting. Hospitalization costs associated with MRSA infections are substantially greater than those associated with methicillin-sensitive S. aureus (MSSA) infections, and MRSA has wider economic effects that involve indirect costs to the patient and to society. In addition, there is some evidence suggesting that MRSA infections increase morbidity and the risk of mortality. Glycopeptides are the backbone antibiotics for the treatment of MRSA infections. However, several recent reports have highlighted the limitations of vancomycin, and its role in the management of serious infections is now being reconsidered. Several new antimicrobials demonstrate in vitro activity against MRSA and other Gram-positive bacteria. Data from large surveys indicate that linezolid, daptomycin, and tigecycline are almost universally active against MRSA. This review will briefly discuss the epidemiology, costs, outcome, and therapeutic options for the management of MRSA infections.
Collapse
Affiliation(s)
- Giuseppe Ippolito
- National Institute for Infectious Diseases Lazzaro Spallanzani, Via Portuense 293, 00149 Rome, Italy.
| | | | | | | | | |
Collapse
|
9
|
Abstract
Despite the medical advances achieved during the last century to fight against bacteria, viruses, fungi and parasites, infectious diseases are still a major cause of death, disability, and social and economic upheaval for millions around the world. Challenges remain in countering microorganisms even where antibiotics and vaccines are available. Much remains to be learned about basic aspects of the host-pathogen relationship and the complexity of the immune response to infection. Animal models represent a powerful tool to dissect the host response to infection, as well as the pathogenesis of the microbe. One of the advantages of using animal models is that both genetic and environmental factors that may influence the course of an infection can be controlled, allowing a precise cause-effect analysis of the host-pathogen interactions. In addition, there are no real alternatives to whole animal models in the study of integrative physiology and dynamic pathophysiologic alterations. The use of animal models has also proven invaluable for testing the efficacy of experimental antimicrobial agents and their therapeutic regimes. The mouse model is the most widely used for many reasons, including its cost effectiveness, the high number of immunological reagents available for this species, and the relative ease of biocontainment. Mouse strains with specific properties such as transgenic mouse strains with gene insertion or targeted mutation (knock-out) are very effective tools for studying the role of specific genes controlling the immune response to infectious pathogens. Murine models will remain the most appropriate tool for evaluating new therapeutic strategies for the treatment of various diseases. The closer the model is adapted to the human disease, the more reliable will be the results.In this chapter, the experimental procedures required to establish a mouse model of cutaneous and soft tissue infection are detailed. This model has provided invaluable insights into the pathogenicity of the agent for the human host.
Collapse
Affiliation(s)
- Eva Medina
- Infection Immunology Research Group, Department of Microbial Pathogenesis, Helmholtz Centre for Infection Research, Braunschweig, Germany
| |
Collapse
|
10
|
Segreti J. Empirical therapy for serious Gram-positive infections: making the right choice. Clin Microbiol Infect 2009; 15 Suppl 6:5-10. [DOI: 10.1111/j.1469-0691.2009.03061.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
11
|
May AK, Stafford RE, Bulger EM, Heffernan D, Guillamondegui O, Bochicchio G, Eachempati SR. Treatment of Complicated Skin and Soft Tissue Infections. Surg Infect (Larchmt) 2009; 10:467-99. [DOI: 10.1089/sur.2009.012] [Citation(s) in RCA: 111] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Affiliation(s)
- Addison K. May
- Division of Trauma and Surgical Critical Care, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Renae E. Stafford
- Department of Surgery, Division of Trauma/Critical Care, University of North Carolina School of Medicine, Chapel Hill, North Carolina
| | - Eileen M. Bulger
- Department of Surgery, University of Washington Harborview Medical Center, Seattle, Washington
| | - Daithi Heffernan
- Department of Surgery, Brown University, Rhode Island Hospital, Providence, Rhode Island
| | - Oscar Guillamondegui
- Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Grant Bochicchio
- Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland
| | - Soumitra R. Eachempati
- Department of Surgery, New York Weill Cornell Center, New York Presbyterian Hospital, New York, New York
| |
Collapse
|
12
|
Viale P, Stefani S. Vascular catheter-associated infections: a microbiological and therapeutic update. J Chemother 2008; 18:235-49. [PMID: 17129833 DOI: 10.1179/joc.2006.18.3.235] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
The increasing incidence of central venous catheter (CVC)-related infections can be ascribed to the wider indications to central venous catheterization, to the higher attention to this issue paid by clinicians and microbiologists, and to the patient population referred to hospitals, increasingly characterized by different degrees of immunosuppression and often in critical clinical conditions. This phenomenon implies a higher health care burden and higher related costs, as well as a significant attributable mortality, that varies however according to the pathogen involved. The microorganisms most frequently involved in CVC-related infections are coagulase-negative staphylococci, Staphylococcus aureus, aerobic Gram-negative bacilli, and Candida albicans. In the management of suspected or proven central venous catheter-related infections, several issues need to be addressed: the need to remove the device or the possibility of salvage, the immediate start of calculated antibiotic therapy or the possibility of waiting for results of microbiological diagnostics and proceeding to etiologically-guided therapy. The preferred conservative method is the "Antibiotic-Lock technique" (ALT), based on the endoluminal application of antibacterials at extremely high concentrations in situ for a period of time long enough to ensure bactericidal activity. On the other hand, immediate catheter removal and initiation of appropriate calculated therapy immediately after an adequate diagnostic work-up are strongly recommended in a clinical setting of severe sepsis or septic shock.
Collapse
Affiliation(s)
- P Viale
- Clinic of Infectious Diseases, Department of Medical and Morphological Research, Medical School, University of Udine, Italy
| | | |
Collapse
|
13
|
Zoumalan RA, Rosenberg DB. Methicillin-resistant Staphylococcus aureus--positive surgical site infections in face-lift surgery. ACTA ACUST UNITED AC 2008; 10:116-23. [PMID: 18347239 DOI: 10.1001/archfaci.10.2.116] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
OBJECTIVES To determine the incidence of methicillin-resistant Staphylococcus aureus (MRSA)-positive surgical site infections after face-lift surgery and to discuss the screening, prevention, and treatment of such infections. METHODS The patient charts of 780 patients who underwent a deep-plane rhytidectomy between 2001 and 2007 were reviewed for postoperative wound infections. Culture results and sensitivities were recorded. To our knowledge, this is the first study that documents MRSA-positive surgical site infections after face-lift surgery. RESULTS Five of 780 patients (0.6%) who underwent face-lift surgery by the senior surgeon had postoperative surgical site infections. Four of the 5 patients had cultures that were positive for MRSA. Two of these patients (0.3%) required hospitalization and had collections that had to be opened or drained and developed wound breakdown. Both patients eventually responded to wound care along with intravenous and then oral antibiotic therapy. The other 2 MRSA-infected patients responded to oral antibiotic therapy and local wound care alone. The 2 complicated infections occurred on postoperative days 5 and 8. These 2 patients were the only ones among the 5 patients with positive cultures who had known recent contact with another physician or a hospital. All infections occurred in the year 2006, with 3 patients experiencing infection in the last 4 months of the year. Herein, we describe the incidence and sequelae of MRSA infections and colonization. The 2 major different subsets of MRSA are community-acquired MRSA and health care-associated MRSA. Surgical site infections that are positive for MRSA blur this division, which affects many aspects of the course of disease and treatment. We also discuss strategies for screening, preventing, and treating MRSA surgical site infections. CONCLUSIONS Methicillin-resistant S aureus-positive surgical site infection is an increasingly problematic issue in all surgical fields. In the future, MRSA-positive infections will be more prevalent and will require well-developed screening, prevention, and treatment strategies.
Collapse
Affiliation(s)
- Richard A Zoumalan
- Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology-Head and Neck Surgery, Lennox Hill-Manhattan Eye, Ear, and Throat Hospital, NY, NY, USA
| | | |
Collapse
|
14
|
In vitro antimicrobial activity of telavancin against methicillin-resistant Staphylococcus aureus clinical isolates from Japan (2006). J Antibiot (Tokyo) 2008; 60:709-12. [PMID: 18057701 DOI: 10.1038/ja.2007.91] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
In vitro antimicrobial activity of telavancin, a rapidly bactericidal lipoglycopeptide, was evaluated against 1500 strains of MRSA recently isolated in Japan. Telavancin had potent activity, with MIC values that ranged from 0.12 microg/ml to 0.5 microg/ml and a MIC90 value of 0.5 microg/ml. The MIC90s of vancomycin and linezolid were 1.0microg/ml and 2 microg/ml, respectively. No vancomycin intermediate resistant or vancomycin-resistant MRSAs were detected in this surveillance study.
Collapse
|
15
|
Eisenstein B. Treatment challenges in the management of complicated skin and soft-tissue infections. Clin Microbiol Infect 2008; 14 Suppl 2:17-25. [DOI: 10.1111/j.1469-0691.2008.01922.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
16
|
Overbye KM, Mordekhay D. AM-7359--a novel oxazolidinone with low resistance potential and potent activity against drug resistant pathogens. J Chemother 2007; 19:249-55. [PMID: 17594918 DOI: 10.1179/joc.2007.19.3.249] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
AM-7359 is a member of a novel series of oxazolidinones with antimicrobial activity against pathogens resistant to multiple antibiotics. Potent antibiotics with limited drug cross resistance to current therapeutic agents are needed for the treatment of drug resistant pathogens. This study investigated the resistance development to linezolid (LZD) and AM-7359 by key pathogens and the degree of cross resistance between these two oxazolidinones. Both AM-7359 and LZD, demonstrates a low frequency of resistance development. After 30 passages and selection for resistant development of four different Staphylococcus aureus and Enterococus faecium strains the minimum inhibitory concentration (MIC) for AM-7359 was 1 <or= microg/ml compared to 32 to 256 microg/ml for LZD. In cross resistance studies AM-7359 demonstrated MICs of 0.5 to 1 microg/ml against the resistant strains selected on LZD. LZD MICs against the resistant strains selected on AM-7359 were 32-64 microg/ml.
Collapse
Affiliation(s)
- K M Overbye
- Infectious Disease, Merck Research Laboratories, Rahway, New Jersey 07065, USA.
| | | |
Collapse
|
17
|
Krige JE, Lindfield K, Friedrich L, Otradovec C, Martone WJ, Katz DE, Tally F. Effectiveness and duration of daptomycin therapy in resolving clinical symptoms in the treatment of complicated skin and skin structure infections. Curr Med Res Opin 2007; 23:2147-56. [PMID: 17669231 DOI: 10.1185/030079907x219652] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVE Compare the rapidity of the resolution of clinical signs and symptoms of complicated skin and skin structure infections (cSSSIs) caused by gram-positive organisms between daptomycin and comparator agents. PATIENTS AND METHODS A subset of South African patients with gram-positive cSSSIs and no or one comorbid condition from two phase III clinical trials were included in the analysis. Patients were treated with daptomycin (n = 174) or comparator (penicillinase-resistant penicillins [n = 146] or vancomycin [n = 6]). The presence and severity of eight clinical signs and symptoms were evaluated at baseline, day 3 or 4 of treatment, end of therapy, and at test of cure (6-20 days after the last dose). RESULTS Of the 326 patients included in this analysis, the clinical success rates between daptomycin and comparator treatments was comparable. Overall, the severity of symptoms in the daptomycin-treated patients improved more quickly (p = 0.04) than comparator treatment. At the day 3/4 evaluation, of the eight signs and symptoms, severity significantly decreased for induration (p = 0.03) and erythema (p = 0.05); a statistical trend was noted for necrotic tissue (p = 0.10) and edema (p = 0.10) in daptomycin-treated patients. Daptomycin treatment resulted in a shorter median duration of therapy than those receiving comparator treatment (7 vs. 8 days, p < 0.0001). Both treatments were well tolerated. CONCLUSION Daptomycin produced a more rapid clinical improvement than comparators, as evidenced by significant reductions in the severity of induration and erythema, with a shorter duration of antibiotic therapy. However, this population was relatively young and healthy; therefore, these results may not be generalizable to all populations.
Collapse
Affiliation(s)
- Jake E Krige
- University of Cape Town Health Sciences Faculty, Cape Town, South Africa
| | | | | | | | | | | | | |
Collapse
|
18
|
Ferrara AM. Treatment of hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 2007; 30:19-24. [PMID: 17475449 DOI: 10.1016/j.ijantimicag.2007.02.011] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2006] [Accepted: 02/15/2007] [Indexed: 11/26/2022]
Abstract
Nosocomial pneumonia and ventilator-assisted pneumonia may be polymicrobial and can be caused by a wide spectrum of pathogens. Potentially multidrug-resistant microorganisms often represent the 'core' pathogens of the most severe infections. Among Gram-positive pathogens, methicillin-resistant Staphylococcus aureus (MRSA) plays a key role, mainly in mechanically ventilated patients or in patients with specific risk factors. The mainstay of treatment for MRSA pneumonia has been glycopeptide antibiotics, i.e. vancomycin and, to a lesser extent, teicoplanin. However, owing to its insufficient penetration into lung compartments, vancomycin may result in therapeutic failure or slow clinical responses. Moreover, vancomycin serum levels must be monitored in order to minimise nephrotoxicity and to maximise the concentration in the lung. Finally, the emergence of staphylococci isolates with reduced susceptibility to vancomycin suggests that glycopeptides should no longer be considered as first-line antibacterial agents for Gram-positive lung infections. Among new therapeutic options, linezolid may be an appropriate choice for MRSA pulmonary infections owing to its good pharmacokinetic profile in the lung and its acceptable tolerability, especially in patients with renal insufficiency or in those receiving other nephrotoxic agents. However, to contain the increasing emergence of drug resistance among hospitalised patients, these novel antimicrobial agents should be used judiciously, restricting their use to patients not responsive to, or intolerant of, glycopeptides. Other new drugs under development appear to be promising and deserve further evaluation.
Collapse
Affiliation(s)
- Anna M Ferrara
- Department of Haematological, Pneumological, Cardiovascular and Surgical Sciences, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Viale Taramelli 5, 27100 Pavia, Italy.
| |
Collapse
|
19
|
Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus: Management Principles and Selection of Antibiotic Therapy. Dermatol Clin 2007; 25:157-64, vi. [DOI: 10.1016/j.det.2007.01.007] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
20
|
Marra A, Dib-Hajj F, Lamb L, Kaczmarek F, Shang W, Beckius G, Milici AJ, Medina I, Gootz TD. Enterococcal virulence determinants may be involved in resistance to clinical therapy. Diagn Microbiol Infect Dis 2007; 58:59-65. [PMID: 17300898 DOI: 10.1016/j.diagmicrobio.2006.11.024] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2006] [Accepted: 11/21/2006] [Indexed: 11/28/2022]
Abstract
The ability of enterococci to acquire resistance to antibiotics and form biofilms in vivo makes these infections, endocarditis in particular, especially difficult to treat. A collection of clinical enterococcal isolates was screened for the presence of various virulence determinants and in an in vitro assay for biofilm formation. Isolates were chosen for the presence or absence of the genes for Esp and gelatinase and different in vitro biofilm phenotypes, and were evaluated in a rat model of endocarditis; all colonized vegetations to similar degrees. Treatment with vancomycin resulted in a 2.7-log reduction in colony-forming unit (CFU) in vegetations for an esp(+)/gel(-) strain, compared with no reduction in CFU for an esp(+)/gel(+) or an esp(-)/gel(-) isolate. These results suggest that although there may not be an absolute role for individual virulence determinants in infectivity, combinations of factors may play a role in allowing a biofilm infection to be more resistant to therapy.
Collapse
Affiliation(s)
- Andrea Marra
- Pfizer Global Research and Development, Groton, CT 06340, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: Report from the SENTRY Antimicrobial Surveillance Program (1998–2004). Diagn Microbiol Infect Dis 2007; 57:7-13. [PMID: 17059876 DOI: 10.1016/j.diagmicrobio.2006.05.009] [Citation(s) in RCA: 290] [Impact Index Per Article: 17.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2006] [Accepted: 05/17/2006] [Indexed: 11/23/2022]
Abstract
The morbidity and cost for cure associated with skin and soft tissue infections (SSTIs) have recently become more complicated because of the increasing prevalence of multidrug-resistant pathogens associated with this healthcare problem. The SENTRY Antimicrobial Surveillance Program has been monitoring SSTI since 1997, and now presents data from 3 continents over a 7-year period (1998-2004). Isolates were tested by reference broth microdilution methods at a central laboratory using the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards) methods and interpretative criteria. The predominant pathogens included Staphylococcus aureus (ranked 1st in all geographic regions), Pseudomonas aeruginosa, Escherichia coli, and Enterococcus spp. A considerable variation in the methicillin (oxacillin)-resistant S. aureus rate was noted between countries and continents, with the overall rate highest in North America (35.9%) compared with Latin America (29.4%) and Europe (22.8%). Vancomycin-resistant Enterococcus spp. increased in Europe (4.1%) and North America (6.2%) during the period, but remained low and relatively unchanged in Latin America. Among the P. aeruginosa isolates tested, susceptibility to imipenem was much lower in Latin America (65.3%) compared with the other regions (80.7-88.7%), and resistance being associated with an increase in metallo-beta-lactamase-producing strains in Latin America and in some European countries. Multidrug-resistant strains of P. aeruginosa were also more of a concern in Latin America (24.7%) compared with Europe (10.8%) or North America (3.2%). Latin America also had the highest occurrence of extended-spectrum beta-lactamase-producing isolates among E. coli (15.1%) and Klebsiella spp. (48.0%) when compared with other regions. Continued surveillance of pathogen prevalence and antimicrobial resistance patterns should provide information that is important to improve empiric care particularly in the hospital environment.
Collapse
Affiliation(s)
- Gary J Moet
- JMI Laboratories, North Liberty, IA 52317, USA
| | | | | | | | | |
Collapse
|
22
|
Elston DM. Community-acquired methicillin-resistant Staphylococcus aureus. J Am Acad Dermatol 2007; 56:1-16; quiz 17-20. [PMID: 17190619 DOI: 10.1016/j.jaad.2006.04.018] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2005] [Revised: 04/05/2006] [Accepted: 04/11/2006] [Indexed: 12/11/2022]
Abstract
UNLABELLED Published data confirm that community-acquired methicillin-resistant Staphylococcus aureus (MRSA) infections are increasing in incidence in both urban and rural settings. The statistical risk is higher for athletes, military personnel, prison inmates, intravenous drug abusers, the homeless, children in daycare, and certain Native American groups, but the infections are by no means restricted to these populations. Roughly 85% of the infections involve the skin and subcutaneous tissue, with the most common presentations being an abscess or folliculitis. The typical associated gene cassette is quite small and codes only for methicillin resistance. Abscesses generally respond to drainage. LEARNING OBJECTIVE At the conclusion of this learning activity, participants should recognize groups at high risk for community-acquired MSRA infections and manage these infections appropriately.
Collapse
Affiliation(s)
- Dirk M Elston
- Department of Dermatology, Geisinger Medical Center, Danville, PA 17821, USA.
| |
Collapse
|
23
|
Cunha BA. Antimicrobial therapy of multidrug-resistant Streptococcus pneumoniae, vancomycin-resistant enterococci, and methicillin-resistant Staphylococcus aureus. Med Clin North Am 2006; 90:1165-82. [PMID: 17116442 DOI: 10.1016/j.mcna.2006.07.007] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Antibiotic resistance among pneumococci, enterococci, and staphylococci has become increasingly important in recent decades. Clinicians should be familiar with the nuances of antibiotic susceptibility testing and interpretation in selecting antibiotics for these infections. The clinical significance of penicillin-resistant Streptococcus pneumoniae, macrolide-resistant S pneumoniae, and multidrug-resistant S pneumoniae is discussed. The clinical spectrum and therapeutic approach to Enterococcus faecalis (i.e., vancomycin-sensitive enterococci) and E faecium (i.e., vancomycin-resistant enterococci) are discussed. Differences in therapeutic approach between methicillin-sensitive Staphylococcus aureus and methicillin-resistant S aureus (MRSA) infections are reviewed. Differences between in vitro susceptibility testing and in vivo effectiveness of antibiotics for hospital-acquired MRSA (HA-MRSA) are described. Finally, the clinical features of infection and therapy of HA-MRSA and community-acquired MRSA (CA-MRSA) infections are compared.
Collapse
Affiliation(s)
- Burke A Cunha
- State University of New York School of Medicine, Stony Brook, NY, USA
| |
Collapse
|
24
|
Cilli F, Aydemir S, Tunger A. In vitro activity of daptomycin alone and in combination with various antimicrobials against Gram-positive cocci. J Chemother 2006; 18:27-32. [PMID: 16572890 DOI: 10.1179/joc.2006.18.1.27] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
The increasing prevalence of resistant Gram-positive cocci requires the need to search for more effective agents and synergistic combinations. Forty-two vancomycin-resistant Enterococcus faecium (VREF), 30 methicillin-resistant Staphylococcus aureus (MRSA) and 36 Staphylococcus epidermidis (MRSE) strains were studied. Minimum inhibitory concentrations (MICs) were determined and synergy testing was performed by using E test for daptomycin, ampicillin-sulbactam, piperacillin-tazobactam and ticarcillin-clavulanate against staphylococci; for daptomycin, ampicillin, rifampin, and gentamicin against enterococci. Daptomycin in combination with ampicillin, rifampin, and gentamicin was tested against enterococci; daptomycin in combination with ampicillin-sulbactam, piperacillin-tazobactam, and ticarcillin-clavulanate was tested against staphylococci. Interaction categories were defined by the fractional inhibitory concentration (FIC) index. All strains of staphylococci and enterococci were susceptible to daptomycin. All three combinations showed synergy against more than 70% of the MRSA strains. Daptomycin in combination with ampicillin, rifampin, and gentamicin against enterococci showed synergies of 64.2%, 57.1% and 21.4%, respectively. This study indicates that daptomycin alone and combined with beta-lactams seems to be effective against MRSA, but further in vitro and in vivo studies on the subject are required before clinical use can be recommended.
Collapse
Affiliation(s)
- F Cilli
- Ege University Medical School Department of Clinical Microbiology, Izmir, Turkey.
| | | | | |
Collapse
|
25
|
Murphy CK, Mullin S, Osburne MS, van Duzer J, Siedlecki J, Yu X, Kerstein K, Cynamon M, Rothstein DM. In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50:827-34. [PMID: 16495239 PMCID: PMC1426431 DOI: 10.1128/aac.50.3.827-834.2006] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
We describe novel rifamycin derivatives (new chemical entities [NCEs]) that retain significant activity against a comprehensive collection of Staphylococcus aureus strains that are resistant to rifamycins. This collection of resistant strains contains 21 of the 26 known single-amino-acid alterations in RpoB, the target of rifamycins. Some NCEs also demonstrated a lower frequency of resistance development than rifampin and rifalazil in S. aureus as measured in a resistance emergence test. When assayed for activity against the strongest rifamycin-resistant mutants, several NCEs had MICs of 2 microg/ml, in contrast to MICs of rifampin and rifalazil, which were 512 microg/ml for the same strains. The properties of these NCEs therefore demonstrate a significant improvement over those of earlier rifamycins, which have been limited primarily to combination therapy due to resistance development, and suggest a potential use of these NCEs for monotherapy in several clinical indications.
Collapse
|
26
|
Lesho EP, Wortmann GW, Craft D, Moran KA. De novo daptomycin nonsusceptibility in a clinical isolate. J Clin Microbiol 2006; 44:673. [PMID: 16455945 PMCID: PMC1392681 DOI: 10.1128/jcm.44.2.673.2006] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Rybak MJ. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Clin Microbiol Infect 2006; 12 Suppl 1:24-32. [PMID: 16445721 DOI: 10.1111/j.1469-0691.2006.01342.x] [Citation(s) in RCA: 74] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
In the face of increasing resistance to currently available antibiotics, there is a continued interest in the development of new drugs to treat Gram-positive infections. One such agent is the cyclic lipopeptide daptomycin-licensed in the USA for treatment of Gram-positive complicated skin and skin structure infections (cSSSIs) in 2003 and currently awaiting European approval for a similar indication (complicated skin and soft tissue infections). Daptomycin exerts its rapid bactericidal effect through insertion into and subsequent depolarisation of the bacterial cell membrane, a mode of action unlike that of any other available antibiotic. This novel mechanism of action makes the development of cross-resistance between daptomycin and other antibiotic classes unlikely. Daptomycin is highly active in vitro against a range of Gram-positive pathogens, including both susceptible and multidrug-resistant staphylococci and enterococci. Bactericidal activity has also been demonstrated against both growing and stationary-phase organisms, suggesting potential utility in the treatment of deep-seated infections. Two pivotal clinical studies comparing daptomycin 4 mg/kg per day intravenously with vancomycin or oxacillin-class antibiotics demonstrated the efficacy of daptomycin for treatment of cSSSIs. Daptomycin was well tolerated, with most adverse events considered to be unrelated to study medication, of mild-to-moderate intensity, and with a frequency and distribution similar to those associated with comparator antibiotics. The favourable clinical profile and low potential for development of resistance combine to make daptomycin a promising alternative to current agents for treatment of Gram-positive bacterial infections.
Collapse
Affiliation(s)
- M J Rybak
- Anti-Infective Research Laboratory, Wayne State University, Detroit, Michigan 48201, USA.
| |
Collapse
|
28
|
Abstract
PURPOSE OF REVIEW This review examines neonatal bacterial skin infections with respect to host immunity, bacterial pathogens, patterns of infection, and new therapeutic approaches. RECENT FINDINGS Advances have been made in our understanding of innate host defense and the emerging role of cutaneous antimicrobial peptides of the cathelicidin and defensin families. Toll-like receptors are being investigated with respect to their interactions with bacteria and other components of the innate immune defense, such as the antimicrobial peptides. The epidermal barrier remains an active area of research. Studies confirm that maintaining an intact epidermal barrier by minimizing exposure to soap and by not removing vernix caseosa are simple measures to improve skin barrier function. Active barrier-enhancing measures such as the application of topical emollients have shown mixed results in the prevention of nosocomial infection. A meta-analysis of studies performed in developed countries showed a trend of increasing risk for coagulase-negative staphylococcal infection. By contrast, a randomized controlled trial showed that infants treated with sunflower oil are less likely to experience nosocomial infections than are control infants. Infants with bacteremia and no known source of infection should be carefully examined because cutaneous abscesses have been shown to be an important nidus of infection. Methicillin-resistant Staphylococcus aureus is reaching epidemic proportions, making surface cultures an essential part of the evaluation of cutaneous bacterial infection. SUMMARY New insights have been gained regarding the basic science of neonatal host defense and these advances may produce new ways of approaching the prevention and treatment of bacterial skin infections in the newborn period.
Collapse
Affiliation(s)
- April A Larson
- Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
| | | |
Collapse
|
29
|
Abstract
There is a clinical need for new treatment options for serious Gram-positive infections. Recently introduced agents such as the newer fluoroquinolones and the ketolide telithromycin have limited use as they do not cover methicillin-resistant Staphylococcus aureus (MRSA) or glycopeptide-resistant enterococci (GRE). The clinical use of the streptogramin combination quinupristin/dalfopristin, which has activity against MRSA and vancomycin-resistant Enterococcus faecium, is limited because administration is via a slow infusion of a large volume. The oxazolidinone linezolid is active against MRSA and GRE but resistant organisms and treatment failures have been reported. A number of compounds currently in development show promise, the new glycopeptides oritavancin, dalbavancin and the glycolipodepsipeptide ramoplanin, as well as the new tetracyclines tigecycline and BAY73-7388. However, in some cases, there is concern that resistance may develop quickly to new compounds that are based on existing antimicrobial agents. Therefore daptomycin, a novel lipopeptide with a unique mode of action, is of particular interest. Daptomycin is active against MRSA (including vancomycin-resistant strains) and GRE. Daptomycin displays rapid concentration-dependent killing and is bactericidal even in the stationary phase of growth. Daptomycin-resistant strains are very difficult to generate in vitro. A dosage of 4 mg/kg intravenous once a day has been shown to be efficacious in two evaluator-blinded trials of complicated skin and soft tissue infections with clinical success rates similar for daptomycin and comparators (vancomycin or penicillinase-resistant penicillins). With its activity against key Gram-positive pathogens, including resistant strains, daptomycin has potential as a valuable addition to the available treatment options for serious Gram-positive infections.
Collapse
Affiliation(s)
- P M Shah
- Klinikum der Wolfgang Goethe-Universitat, Zentrum der Inneren Medizin, Medizinische Klinik III, Schwerpunkt Infektiologie, Theodoe-Srwen-Kai 7, D-60590 Frankfurt, Germany
| |
Collapse
|